AMT-130 gene therapy: a promising disease-modifying approach for Huntington’s disease
Open Access
- 10 December 2025
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 1144-1145
Abstract
Huntington’s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by expanded Cytosine-Adenine-GuanineCAG repeats in the huntingtin (HTT) gene, leading to the production and accumulation of mutant huntingtin protein and subsequent neuronal dysfunction and loss. Current management remains largely symptomatic, with no established disease-modifying therapy. AMT-130 represents a novel and promising approach aimed at directly targeting the underlying molecular pathology of HD. AMT-130 is a one-time gene therapy that utilizes an adeno-associated virus serotype 5 (AAV5) vector to deliver an engineered microRNA (miHTT) into the caudate and putamen via stereotactic intracerebral infusion. This microRNA selectively reduces HTT mRNA levels, resulting in sustained lowering of mutant huntingtin protein. Preclinical studies in both large-animal and rodent models have demonstrated broad vector distribution, long-term expression, significant reduction in huntingtin levels, improved motor performance, decreased neuronal degeneration, and prolonged survival. Early Phase I/II clinical data indicate a favorable safety profile, reductions in neurofilament light chain levels, and stabilization of motor and functional decline, particularly in high-dose cohorts, suggesting a potential slowing of disease progression. While long-term efficacy and broader clinical validation are still required, AMT-130 shows strong potential to shift HD treatment from purely symptomatic care toward meaningful disease modification. Its success may also pave the way for microRNA-based therapies in other neurodegenerative disorders.Keywords
This publication has 8 references indexed in Scilit:
- Evidence-Based Review on Symptomatic Management of Huntington’s DiseaseJournal of Movement Disorders, 2024
- Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease modelsBrain, 2024
- Prevalence of neurocognitive disorder in Huntington’s disease using the Enroll-HD datasetFrontiers in Neurology, 2023
- AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington’s disease mouse modelBrain, 2022
- Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐AnalysisMovement Disorders, 2022
- AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse ModelsMolecular Therapy - Methods & Clinical Development, 2019
- AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig ModelMolecular Therapy, 2018
- Huntington's disease: a clinical reviewOrphanet Journal of Rare Diseases, 2010